Data / Drug companies / Diclofenac epolamine
Diclofenac epolamine: 11 companies and 14 products in the FDA NDC directory
Diclofenac epolamine is listed in the FDA National Drug Code Directory by 11 companies, with 14 products in commercial distribution. 0 of the products (0.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are system, and the newest product started marketing on June 8, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 11
- Products
- 14
- Generic (ANDA) products
- 0 (0.0%)
- Application numbers
- 2
- Routes
- Topical
- Brand names
- Licart, Flector
- openFDA record search
- api.fda.gov
Companies that list diclofenac epolamine
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Advanced Rx of Tennessee, LLC | 2 | system | Authorized generics (NDA) | June 19, 2024 |
| Asclemed USA, Inc. | 2 | system | Authorized generics (NDA) | November 18, 2022 |
| Ibsa Pharma Inc. | 2 | system | New drug applications (NDA) | November 1, 2020 |
| Acertis Pharmaceuticals, LLC | 1 | system | New drug applications (NDA) | September 1, 2020 |
| Hawaii Repack, Inc. | 1 | system | Authorized generics (NDA) | November 18, 2022 |
| Phoenix RX LLC | 1 | system | Authorized generics (NDA) | November 18, 2022 |
| Preferred Pharmaceuticals Inc. | 1 | system | Authorized generics (NDA) | June 8, 2026 |
| Quality Care Products, LLC | 1 | system | Authorized generics (NDA) | August 15, 2023 |
| Sportpharm LLC | 1 | system | Authorized generics (NDA) | November 18, 2022 |
| Teva Pharmaceuticals USA, Inc. | 1 | system | Authorized generics (NDA) | May 1, 2020 |
| Yaral Pharma Inc. | 1 | system | Authorized generics (NDA) | November 18, 2022 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| System | 14 | 100% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Authorized generics (NDA) | 11 | 78.6% |
| New drug applications (NDA) | 3 | 21.4% |
Pharmacologic classes
| Class | Products |
|---|---|
| Nonsteroidal Anti-inflammatory Drug | 14 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.